TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25522560

Group type: EXPERIMENTAL
Intervention: Macrolides
Number of subjects: 165

Group type: COMPARATOR
Intervention: Cephalosporins
Number of subjects: 165
Study: 22515904

Group type: EXPERIMENTAL
Intervention: Continuous ultrasonic irrigation (CUI)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Passive ultrasonic irrigation (PUI)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Positive pressure irrigation (PPI)
Number of subjects: 360
Study: 20450670

Group type: EXPERIMENTAL
Intervention: OCCI (on-axis clear corneal incision)
Number of subjects: 39

Group type: COMPARATOR
Intervention: TCCI (temporal clear corneal incision)
Number of subjects: 39
Study: 19046225

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Blood glucose awareness training (BGAT)
Number of subjects: 86
Study: 16494857

Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 40
Study: 15259901

Group type: EXPERIMENTAL
Intervention: Stavudine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Zidovudine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 28
Study: 11777120

Group type: EXPERIMENTAL
Intervention: Problem-solving communication training (PSCT) alone, 18 sessions
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Behavior management training (BMT) for 9 sessions followed by PSCT for 9 sessions (BMT/PSCT)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Both treatments (PSCT and BMT/PSCT)
Number of subjects: 97
Study: 9298779

Group type: EXPERIMENTAL
Intervention: 95% maximal exercise intensity swimming intervals (95% ITS)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 70% maximal exercise intensity swimming intervals (70% ITS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control samples taken on a rest day (R)
Number of subjects: 8
Study: 8410398

Group type: EXPERIMENTAL
Intervention: Treatment associated with higher mortality
Number of subjects: 230

Group type: COMPARATOR
Intervention: Treatment associated with lower mortality
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Symptomatic patients (with urinary incontinence or impotence)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Asymptomatic patients (without urinary incontinence or impotence)
Number of subjects: 230
Study: 3104218

Group type: EXPERIMENTAL
Intervention: HB420 (3.5 mg/tablet)
Number of subjects: 22

Group type: COMPARATOR
Intervention: HB419 (5 mg/tablet)
Number of subjects: 22
Study: 30708349

Group type: EXPERIMENTAL
Intervention: Computerized multi-model cognitive training, 3-4 times per week for 6 months
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Computerized multi-model cognitive training
Number of subjects: 141
Study: 28317094

Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg.kg‐1
Number of subjects: 4494

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4494
Study: 25566694

Group type: EXPERIMENTAL
Intervention: Transfusion threshold <7 g/dl
Number of subjects: 200

Group type: COMPARATOR
Intervention: Transfusion threshold 10 g/dl
Number of subjects: 200
Study: 23307156

Group type: EXPERIMENTAL
Intervention: Bidirectional motor skill training using a 3x1 array keypad for 30 minutes over two consecutive days.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidirectional motor skill training using a 3x3 array keypad for 30 minutes over two consecutive days.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (FDI TMS-MEP stimulus-response curves).
Number of subjects: 0
Study: 20859932

Group type: EXPERIMENTAL
Intervention: Group psychoeducation (8 sessions)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 39
Study: 19880616

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17122226

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Spectral entropy monitoring
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 140
Study: 15177955

Group type: EXPERIMENTAL
Intervention: Intraoperative mitomycin C (0.5 mg/ml for 5 minutes)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 60
Study: 11224634

Group type: EXPERIMENTAL
Intervention: Calcium heparin 5,000 units every 8 hours
Number of subjects: 936

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily (plus two additional saline injections)
Number of subjects: 936
Study: 9010944

Group type: EXPERIMENTAL
Intervention: Articaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prilocaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 30
Study: 7899804

Group type: EXPERIMENTAL
Intervention: Arteflene (Ro 42-1611) 300 mg or higher doses
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Arteflene (Ro 42-1611) 100, 300, 900, 1800, 2700, and 3600 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Arteflene (Ro 42-1611)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 3661277

Group type: EXPERIMENTAL
Intervention: Moderate alcohol expected
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High alcohol expected
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: None alcohol expected
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumed
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High alcohol consumed
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: None alcohol consumed
Number of subjects: 39
Study: 31209720

Group type: EXPERIMENTAL
Intervention: Sterilized probiotic with 5.85 g polydextrose daily for 1 week (Group A)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Sterilized probiotic without polydextrose daily for 1 week (Group B)
Number of subjects: 163
Study: 29526580

Group type: EXPERIMENTAL
Intervention: Home particle repositioning maneuver (PRM) once weekly for five years
Number of subjects: 309

Group type: COMPARATOR
Intervention: Control group (no home PRM)
Number of subjects: 309
Study: 26607646

Group type: EXPERIMENTAL
Intervention: 80 kVp, 600 mAs, 35 ml CM at an injection rate of 3.5-4.5 ml/s
Number of subjects: 94

Group type: COMPARATOR
Intervention: 100 kVp, 600 mAs, 70 ml CM at an injection rate of 4.5-5.5 ml/s
Number of subjects: 94
Study: 25012543

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1402
Study: 22815697

Group type: EXPERIMENTAL
Intervention: Cognitive exercises (CE)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard cognitive training (CP)
Number of subjects: 36
Study: 20361904

Group type: EXPERIMENTAL
Intervention: Divalproex sodium extended-release (ER) at a daily dosage initiated at 20 mg/kg for 21 days
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 19368096

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily for 6 months
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 15910120

Group type: EXPERIMENTAL
Intervention: Cognitive switching tasks (verbal and nonverbal)
Number of subjects: 719
Study: 16388203

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Isoxsuprine
Number of subjects: 100
Study: 10577853

Group type: EXPERIMENTAL
Intervention: Chemotherapy (mitomycin 20 mg/m² IV on day 1, followed by tegafur 400 mg bid daily for 3 months)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control (no further treatment)
Number of subjects: 148
Study: 8914885

Group type: EXPERIMENTAL
Intervention: 3 million U streptokinase
Number of subjects: 52

Group type: COMPARATOR
Intervention: 1.5 million U streptokinase
Number of subjects: 52
Study: 1874226

Group type: EXPERIMENTAL
Intervention: 3 in 1 femoral nerve block
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lateral cutaneous nerve block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 0
Study: 7089645

Group type: EXPERIMENTAL
Intervention: Electrical clipping
Number of subjects: 200

Group type: COMPARATOR
Intervention: Razor shaving
Number of subjects: 200
Study: 30321061

Group type: EXPERIMENTAL
Intervention: Lumenis® M22TM intense pulsed light (IPL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 5% tea tree oil (control)
Number of subjects: 40
Study: 29961161

Group type: EXPERIMENTAL
Intervention: Sirukumab 25 mg every 4 weeks (q4w)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg every 4 weeks (q4w)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg every 4 weeks (q4w)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg every 2 weeks (q2w)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26693901

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 5543

Group type: COMPARATOR
Intervention: Zoledronic Acid (ZA)
Number of subjects: 5543
Study: 24652989

Group type: EXPERIMENTAL
Intervention: FC with rituximab (FCR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FCR
Number of subjects: 0
Study: 21956255

Group type: EXPERIMENTAL
Intervention: Micafungin 50 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Micafungin 100 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Micafungin 150 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Micafungin (all doses)
Number of subjects: 0
Study: 21410035

Group type: EXPERIMENTAL
Intervention: Neroli oil (experimental group)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sunflower oil (control group)
Number of subjects: 27
Study: 17265519

Group type: EXPERIMENTAL
Intervention: FOLFOX4 (oxaliplatin/5‐fluorouracil/leucovorin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5‐FU/LV (leucovorin/5-fluorouracil)
Number of subjects: 0
Study: 16241027

Group type: EXPERIMENTAL
Intervention: Triple dye
Number of subjects: 185

Group type: COMPARATOR
Intervention: Alcohol
Number of subjects: 185

Group type: COMPARATOR
Intervention: No antiseptic agent
Number of subjects: 185
Study: 12914870

Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg or carvedilol 25 mg twice daily after a 4-week dose titration period
Number of subjects: 49
Study: 10340366

Group type: EXPERIMENTAL
Intervention: Tremacamra (367 microg per nostril per dose, total of 4.4 mg/d)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 7546157

Group type: EXPERIMENTAL
Intervention: CyA‐NOF (7.5 mg/kg)
Number of subjects: 12
Study: 2006518

Group type: EXPERIMENTAL
Intervention: Segmental neoprene‐injected graft (group A)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Total pancreaticoduodenal graft with enteric diversion (group B)
Number of subjects: 17
Study: 7011221

Group type: EXPERIMENTAL
Intervention: Early motion starting on postoperative day 1
Number of subjects: 36

Group type: COMPARATOR
Intervention: Delayed motion starting on postoperative day 7
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both early and delayed groups
Number of subjects: 36
Study: 31709738

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 97

Group type: COMPARATOR
Intervention: Gliclazide modified release 120 mg
Number of subjects: 97
Study: 30193295

Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy (FEC followed by paclitaxel and trastuzumab)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Concurrent chemotherapy (Paclitaxel and trastuzumab followed by FEC and trastuzumab)
Number of subjects: 280
Study: 29240863

Group type: EXPERIMENTAL
Intervention: Efinaconazole 10% topical solution, once-daily for 48 weeks, with two 12-week post-treatment follow-ups (at week 60 and 72)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Efinaconazole 10% topical solution, once-daily for 48 weeks
Number of subjects: 23
Study: 25559903

Group type: EXPERIMENTAL
Intervention: Combined vertical and horizontal plyometric training (VHG)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vertical plyometric training (VG)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Horizontal plyometric training (HG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 40
Study: 24126365

Group type: EXPERIMENTAL
Intervention: XPF thyroid collars (TCs)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard 0.5-mm lead-equivalent TCs
Number of subjects: 144
Study: 22156827

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 99
Study: 19399391

Group type: EXPERIMENTAL
Intervention: Telemonitoring of blood pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telemonitoring combined with regular individualized interventions (like phone calls)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 17415036

Group type: EXPERIMENTAL
Intervention: Quadruple nucleosides
Number of subjects: 170

Group type: COMPARATOR
Intervention: Efavirenz-containing regimen
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 170
Study: 15157254

Group type: EXPERIMENTAL
Intervention: Biotinylated RBCs plus unlabeled allogeneic RBCs (1.0 mL of biotinylated RBCs plus 15 mL per kg of unlabeled allogeneic RBCs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biotinylated RBCs
Number of subjects: 0
Study: 16492007

Group type: EXPERIMENTAL
Intervention: 1-year preventive intervention with practice-nurse support for follow-up of elevated risk patients
Number of subjects: 7092

Group type: COMPARATOR
Intervention: Control group receiving care as usual
Number of subjects: 7092
Study: 10227554

Group type: EXPERIMENTAL
Intervention: Hawley bite plane (HBP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: superior repositioning splint (SRS)
Number of subjects: 20
Study: 9441111

Group type: EXPERIMENTAL
Intervention: High resolution computer tomography (HRCT) for diagnosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New therapeutic strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-invasive tests for patient stratification
Number of subjects: 0
Study: 2072515

Group type: EXPERIMENTAL
Intervention: Continuous epidural administration of 1% mepivacaine at a rate of 2 ml.hr‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intermittent bolus administration of 1% mepivacaine 4-5 times daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional therapy including infusion of Ringer's solution and diuretics (Control group)
Number of subjects: 40
Study: 6653649

Group type: EXPERIMENTAL
Intervention: Penbutolol (i.v. doses of 3, 6, and 12 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Penbutolol (i.v. doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Penbutolol (oral doses of 40, 80, and 120 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Penbutolol (oral doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Penbutolol (i.v. administration)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Penbutolol (all doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31970794

Group type: EXPERIMENTAL
Intervention: 3D dosimeter, PRESAGE, irradiated under various gantry and couch angles with 6 MV at 800 MU/field.
Number of subjects: 0
Study: 31849296

Group type: EXPERIMENTAL
Intervention: Remote counselling by phone (Group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Remote counselling via text messages (Group 2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard advice from attending physicians (Group 3)
Number of subjects: 120
Study: 28323806

Group type: EXPERIMENTAL
Intervention: Standard pain management plus perioperative nonsteroidal anti-inflammatory drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard pain management plus pregabalin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard pain management
Number of subjects: 0
Study: 27581760

Group type: EXPERIMENTAL
Intervention: Multidisciplinary program group
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Personalized care group
Number of subjects: 256
Study: 25091090

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly (BIW)
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly (QW)
Number of subjects: 752
Study: 21878834

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 338

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 338
Study: 19233766

Group type: EXPERIMENTAL
Intervention: Spyder exoconnector device for clampless proximal anastomosis
Number of subjects: 38
Study: 17894653

Group type: EXPERIMENTAL
Intervention: 10 mg bisacodyl with 2-L sulphate-free electrolyte lavage
Number of subjects: 455

Group type: COMPARATOR
Intervention: 20 mg bisacodyl with 2-L sulphate-free electrolyte lavage
Number of subjects: 455
Study: 14978550

Group type: EXPERIMENTAL
Intervention: Zinc chelate 1 mg/kg daily for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 40
Study: 11915705

Group type: EXPERIMENTAL
Intervention: Intraosseous infusion technique
Number of subjects: 87

Group type: COMPARATOR
Intervention: Traditional drugs
Number of subjects: 87
Study: 9658754

Group type: EXPERIMENTAL
Intervention: Stool myeloperoxidase levels in active inflammatory bowel disease patients
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Stool myeloperoxidase levels after resolution of disease exacerbation
Number of subjects: 89

Group type: COMPARATOR
Intervention: Stool myeloperoxidase levels in normal controls
Number of subjects: 89

Group type: COMPARATOR
Intervention: Stool myeloperoxidase levels in inflammatory disease controls
Number of subjects: 89
Study: 8085688

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g orally every 6 hours)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Cimetidine (continuous intravenous, titrated to maintain gastric pH at 4.0)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No prophylaxis (control)
Number of subjects: 300
Study: 29554208

Group type: COMPARATOR
Intervention: Compliant ads
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Non-compliant ads
Number of subjects: 120

Group type: COMPARATOR
Intervention: User engagement and UGCs
Number of subjects: 120

Group type: COMPARATOR
Intervention: AUDIT scores
Number of subjects: 120

Group type: COMPARATOR
Intervention: Facebook involvement scores
Number of subjects: 120
Study: 28487349

Group type: EXPERIMENTAL
Intervention: Patient-Centred Innovations for Persons with Multimorbidity (details on specific interventions not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group matched on age, sex, enrolment/index date and propensity score (details on specific interventions not provided)
Number of subjects: 0
Study: 25134858

Group type: EXPERIMENTAL
Intervention: Standardized preventive care measures
Number of subjects: 610
Study: 23165743

Group type: COMPARATOR
Intervention: Multifraction radiotherapy (MFRT) - 30 Gy in 10 fractions
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Single-fraction radiotherapy (SFRT) - 8 Gy in 1 fraction
Number of subjects: 235
Study: 20875040

Group type: EXPERIMENTAL
Intervention: Receptive language disorders
Number of subjects: 6051

Group type: EXPERIMENTAL
Intervention: Pragmatic disorders
Number of subjects: 6051

Group type: EXPERIMENTAL
Intervention: Suspected autism
Number of subjects: 6051
Study: 19712155

Group type: EXPERIMENTAL
Intervention: Deltamethrin emulsifiable concentrate (EC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deltamethrin suspension concentrate (SC)
Number of subjects: 0
Study: 17043157

Group type: EXPERIMENTAL
Intervention: Aldosterone (0.7 mug/kg per hour for 10 hours followed by 0.9 mug/kg per hour for 4 hours)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Angiotensin II (2 ng/kg per minute) during placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Angiotensin II (2 ng/kg per minute) during spironolactone (50 mg per day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Spironolactone (50 mg per day)
Number of subjects: 25
Study: 12556676

Group type: EXPERIMENTAL
Intervention: Emergency revascularization
Number of subjects: 302

Group type: COMPARATOR
Intervention: Initial medical stabilization
Number of subjects: 302
Study: 10675427

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (20 ppm for 24 hours, then 5 ppm for 96 hours)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control group (no nitric oxide)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 248
Study: 9479662

Group type: EXPERIMENTAL
Intervention: Destruction of T2 ganglion with intact T3 ganglion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Destruction of T3 ganglion with intact T2 ganglion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Destruction of both T2 and T3 ganglia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Stellate stimulation
Number of subjects: 20
Study: 12959319

Group type: EXPERIMENTAL
Intervention: Tobramycin intravenously (i.v.) over 3-5 min
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tobramycin i.v. over 3-5 min followed by ticarcillin infused i.v. over 20-30 min
Number of subjects: 18

Group type: COMPARATOR
Intervention: Tobramycin alone (TOB phase)
Number of subjects: 18
Study: 3032490

Group type: EXPERIMENTAL
Intervention: ACTH therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Patients with MS
Number of subjects: 35
Study: 31563977

Group type: EXPERIMENTAL
Intervention: Peritonsillar infiltration with 1 mg/kg bupivacaine (0.5%) totaling 5 mL
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Glossotonsillar sulcus infiltration with 1 mg/kg bupivacaine (0.5%) totaling 5 mL
Number of subjects: 50
Study: 30053199

Group type: EXPERIMENTAL
Intervention: Treatment according to a pre-defined algorithm in a tight control regimen
Number of subjects: 222
Study: 27513278

Group type: EXPERIMENTAL
Intervention: Sirolimus therapy for 2 years at doses adjusted to maintain a trough blood level of 5-15 ng/ml
Number of subjects: 63